Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 13.3mmol/5ml) solution for infusion 5ml ampoules (martindale pharmaceuticals ltd - potassium chloride - solution for infusion - 200mg/1ml

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 27mmol/10ml) solution for infusion 10ml ampoules (martindale pharmaceuticals ltd - potassium chloride - solution for infusion - 200mg/1ml

Singapore - Engels - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - ustekinumab - infusion, solution concentrate - ustekinumab 130mg/vial

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - levofloxacin hemihydrate - infusion - 5mg/1ml

Australië - Engels - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 0.2 g/ml - injection, intravenous infusion - excipient ingredients: octanoate; sodium; water for injections - indications as at 27 january 2000: hypoproteinaemia in the acutely ill patient: albumex 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. shock: albumex 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4-5% human albumin is preferred when available. burns: extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins, resulting in hypovolaemic shock and circulatory failure. inititally (during the first 24 hours) there is an increased vascular permeability leading to loss of water and proteins into the extravascular compartment, and haemoconcentration. large volumes of crystalloid solutions should be infused to restore the constricted intravascular fluid space, and smaller amounts of albumex 20 are required to maintain adequate plasma volume and colloid osmotic pressure. adult respiratory distress syndrome

Australië - Engels - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 0.2 g/ml - injection, intravenous infusion - excipient ingredients: water for injections; sodium; octanoate - indications as at 27 january 2000: hypoproteinaemia in the acutely ill patient: albumex 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. shock: albumex 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4-5% human albumin is preferred when available. burns: extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins, resulting in hypovolaemic shock and circulatory failure. inititally (during the first 24 hours) there is an increased vascular permeability leading to loss of water and proteins into the extravascular compartment, and haemoconcentration. large volumes of crystalloid solutions should be infused to restore the constricted intravascular fluid space, and smaller amounts of albumex 20 are required to maintain adequate plasma volume and colloid osmotic pressure. adult respiratory distress syndrome

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

amgen ltd - trastuzumab - powder for solution for infusion - 150mg

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - trastuzumab - powder for solution for infusion - 150mg

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - trastuzumab - powder for solution for infusion - 150mg

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

napp pharmaceuticals ltd - trastuzumab - powder for solution for infusion - 150mg